Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

ASL in Brain Metastasis MRI Following Gamma Knife Treatment

ASL in Diagnostics of Tumor Progression Versus Radionecrosis in Brain Metastasis Following Gamma Knife Treatment.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment. The primary target of the study is to establish the diagnostic performances (specificity, sensitivity) of quantitative measures of ASL in brain metastases suspected of progression/radionecrosis after GK treatment

Who May Be Eligible (Plain English)

Who May Qualify: - Brain metastasis from histologically proven tumor - GK treatment within 4 month prior to the inclusion - Lesions suspected of progression/ radionecrosis : i.e.≥ 25% of the size progression - Lesion size: gadolinium enhanced part of the tumour ≥1 cm Who Should NOT Join This Trial: - Pregnancy - Medical history of primitive brain tumour - MRI incompatibility/ medical history of contrast agent allergy - Claustrophobia - Patient unable to consent - Epilepsia/recent stroke - Patients participating in other studies - Patients without health care insurance Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Brain metastasis from histologically proven tumor * GK treatment within 4 month prior to the inclusion * Lesions suspected of progression/ radionecrosis : i.e.≥ 25% of the size progression * Lesion size: gadolinium enhanced part of the tumour ≥1 cm Exclusion Criteria: * Pregnancy * Medical history of primitive brain tumour * MRI incompatibility/ medical history of contrast agent allergy * Claustrophobia * Patient unable to consent * Epilepsia/recent stroke * Patients participating in other studies * Patients without health care insurance

Treatments Being Tested

OTHER

MRI perfusion sequence

Quantitative analysis

Locations (1)

Service de neuroradiologie, hôpital Pitié Salpêtrière
Paris, France